Published in N Engl J Med on November 18, 1971
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Tumor angiogenesis. N Engl J Med (2008) 11.30
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 4.91
Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev (2008) 4.80
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71
Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol (1995) 4.37
Tumor dormancy in vivo by prevention of neovascularization. J Exp Med (1972) 4.34
Mouse model of angiogenesis. Am J Pathol (1998) 4.28
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer (2007) 4.22
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Contribution of platelets to tumour metastasis. Nat Rev Cancer (2011) 4.16
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med (2009) 3.85
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol (2015) 3.62
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest (2003) 3.31
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature (2014) 3.31
The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 3.26
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A (2012) 3.21
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
Vasculogenic mimicry and tumor angiogenesis. Am J Pathol (2000) 3.19
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Phenotype and genotype of pancreatic cancer cell lines. Pancreas (2010) 3.06
Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol (2010) 3.02
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res (2005) 3.01
Self-regulation of growth in three dimensions. J Exp Med (1973) 2.87
Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest (1999) 2.86
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev (2007) 2.60
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A (2000) 2.47
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol (2008) 2.41
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol (2009) 2.29
Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A (2002) 2.29
Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett (2008) 2.28
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest (2007) 2.28
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2.24
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A (2007) 2.19
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07
Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res (2012) 2.01
Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol (2009) 2.01
Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer (2009) 2.00
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol (2007) 1.99
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96
Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A (2006) 1.96
Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell (2013) 1.93
Human studies of angiogenic gene therapy. Circ Res (2009) 1.92
Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells. PLoS One (2009) 1.92
MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One (2011) 1.90
Vascular endothelial growth factors and vascular permeability. Cardiovasc Res (2010) 1.89
Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology (2008) 1.88
Endothelial cell heterogeneity. Cold Spring Harb Perspect Med (2012) 1.88
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther (2008) 1.84
Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A (2001) 1.83
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol (2011) 1.82
Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood (2010) 1.81
Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci U S A (2009) 1.81
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A (2008) 1.80
An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol (2009) 1.80
Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol (2009) 1.80
Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst (2010) 1.78
Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest (2002) 1.78
MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res (2011) 1.77
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood (2005) 1.74
Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med (1975) 1.74
Targeting the tumor microenvironment. Front Biosci (2007) 1.72
Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res (2012) 1.71
Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer (1999) 1.71
Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med (2003) 1.69
Endothelial progenitor cells in neovascularization of infarcted myocardium. J Mol Cell Cardiol (2008) 1.69
Efficacy of capillary pattern type IIIA/IIIB by magnifying narrow band imaging for estimating depth of invasion of early colorectal neoplasms. BMC Gastroenterol (2010) 1.68
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A (2007) 1.68
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med (2012) 1.68
Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci U S A (2006) 1.66
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med (2012) 1.66
Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol (1994) 1.65
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev (2010) 1.64
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med (2007) 1.64
Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer. World J Gastroenterol (2002) 1.63
PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A (2001) 1.62
Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol (2009) 1.62
Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol (2006) 1.61
Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol (2003) 1.61
Vascular disrupting agents in clinical development. Br J Cancer (2007) 1.60
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem (2011) 1.56
Angiogenesis and vascular remodelling in normal and cancerous tissues. J Math Biol (2008) 1.55
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Angiogenic factors. Science (1987) 15.22
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Role of cell shape in growth control. Nature (1978) 12.46
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med (1995) 7.37
Isolation of a tumor factor responsible for angiogenesis. J Exp Med (1971) 7.12
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42
Human vascular endothelial cells in culture. Growth and DNA synthesis. J Cell Biol (1974) 5.95
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol (1994) 5.76
Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A (1979) 5.70
Tumor angiogenesis. Adv Cancer Res (1985) 5.66
Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res (1977) 5.19
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 5.15
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol (1989) 4.85
Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A (1987) 4.83
Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med (1992) 4.76
Angiogenesis in vitro. Nature (1980) 4.46
Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg (1972) 4.37
Tumor dormancy in vivo by prevention of neovascularization. J Exp Med (1972) 4.34
Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science (1984) 4.27
Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst (1974) 4.05
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol (1994) 3.76
Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med (1996) 3.64
Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst (1995) 3.53
Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation (1999) 3.53
A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci (1996) 3.49
Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol (1976) 3.21
Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg (1966) 3.00
Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest (1994) 2.97
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol (1996) 2.95
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A (1997) 2.88
Self-regulation of growth in three dimensions. J Exp Med (1973) 2.87
How does extracellular matrix control capillary morphogenesis? Cell (1989) 2.84
Polymers for the sustained release of proteins and other macromolecules. Nature (1976) 2.81
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A (2001) 2.81
Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest (1993) 2.71
How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res (1986) 2.69
Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res (1999) 2.58
Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun (1993) 2.56
Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell (1991) 2.52
Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst (1972) 2.52
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst (1994) 2.50
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry (1989) 2.49
Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood (1999) 2.49
Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science (1983) 2.47
A simple procedure for the long-term cultivation of chicken embryos. Dev Biol (1974) 2.46
Tumor angiogenesis. Adv Cancer Res (1974) 2.38
Protamine is an inhibitor of angiogenesis. Nature (1982) 2.30
Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med (1980) 2.27
Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell (1998) 2.17
Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature (1969) 2.16
Fine structure of vascular endothelium in culture. J Ultrastruct Res (1975) 2.15
Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics (1999) 2.12
Betacellulin: a mitogen from pancreatic beta cell tumors. Science (1993) 2.10
Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst (2001) 2.10
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A (1996) 2.07
Involvement of platelets in tumour angiogenesis? Lancet (1998) 2.03
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol (1997) 1.98
Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. J Natl Cancer Inst (1973) 1.95
Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr (1998) 1.95
Isolation and characterization of endothelial progenitor cells from mouse embryos. Development (1998) 1.94
Endothelial growth factors and extracellular matrix regulate DNA synthesis through modulation of cell and nuclear expansion. In Vitro Cell Dev Biol (1987) 1.93
Application of the biological principle of induced osteogenesis for craniofacial defects. Lancet (1981) 1.92
Proceedings: Tumor angiogenesis factor. Cancer Res (1974) 1.86
Influence of geometry on control of cell growth. Biochim Biophys Acta (1975) 1.79
Isolations of a cartilage factor that inhibits tumor neovascularization. Science (1976) 1.79
Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem (1999) 1.78
Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med (1995) 1.78
Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Cell Biochem (1985) 1.77
Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels. Am J Pathol (1975) 1.77
The hemostatic system as a regulator of angiogenesis. J Biol Chem (2000) 1.76
Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med (1975) 1.74
Elevated basic fibroblast growth factor in the serum of patients with Duchenne muscular dystrophy. Ann Neurol (1994) 1.73
Tumor angiogenesis. Rapid induction of endothelial mitoses demonstrated by autoradiography. J Cell Biol (1972) 1.72
Mast cells and tumor angiogenesis. Int J Cancer (1976) 1.71
Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun (1991) 1.67
Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science (1999) 1.67
Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A (1998) 1.66
In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest (1996) 1.65
Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res (2001) 1.64
Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem (1996) 1.63
Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dermatol (1998) 1.60
Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med (1975) 1.60
Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer (1994) 1.60
Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest (1988) 1.58
Angiogenesis: initiation and control. Ann N Y Acad Sci (1982) 1.57
Angiogenesis and breast cancer. J Clin Oncol (1994) 1.56
Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res (2001) 1.55
A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology (1986) 1.55
The vascularization of tumors. Sci Am (1976) 1.51
The generation of endostatin is mediated by elastase. Cancer Res (1999) 1.51